Ernst & Young’s 2012 edition of Beyond Borders, which was recently launched at BIO International Convention at Boston, Massachusetts, will have its India launch soon. The report reviews the global and India scenarios, while proposing an entirely new drug development model: holistic open learning networks (HOLNets).
While the biotech industry’s financial performance might be stabilising, tight funding continues to strain the traditional drug development model. However, this pressure on drug development has led to the evolution of interesting models of partnership on drug development. The report throws more light on such trends in the lifesciences industry.
HOLNETS, which are networks of diverse entities — drug firms, providers, patient groups, social media networks, data analytic firms and more — would pool vast amounts of data, share real-time insights from across the health care ecosystem, and adapt rapidly. HOLNets would build on existing trends and, critically, connect information from across the value chain and cycle of care.
Early examples of initiatives that adopt some (though not all) of these four principles include: The Coalition Against Major Diseases; One Mind for Research; New Drugs for Bad Bugs; The Biomarkers Consortium; CommonMind Consortium and Sage Bionetworks.
EP News Bureau – Mumbai
- Advertisement -
